Citation Impact
Citing Papers
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
2011
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
2011
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
2013
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
2013
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
2013 StandoutNobel
Immunotherapy of cancer in 2012
2012
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
2010
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model
2013
Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
2014
Molecular mechanism and function of CD40/CD40L engagement in the immune system
2009
Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity
2020
Peptide dendrimers: applications and synthesis
2002
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
2013
Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies
2008
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
2014
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Pancreatic Adenocarcinoma
2014 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
2017
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
2015
Immunity, Inflammation, and Cancer
2010 Standout
Immune checkpoint modulation: Rational design of combination strategies
2015
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
2019 Nobel
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
2011 Science
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
2012 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
2014
Multiple Sclerosis
2018 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances Antiparasitic Immunity
2010 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Immune targeting in breast cancer.
2015
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
2016
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
TRAF2 Ser-11 Phosphorylation Promotes Cytosolic Translocation of the CD40 Complex To Regulate Downstream Signaling Pathways
2020
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice
2021 StandoutNobel
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
Immune Therapy for Cancer
2008
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
2012 StandoutNobel
Mechanisms of white matter damage in multiple sclerosis
2014
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
2007
Works of Magi Khalil being referenced
Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody
2007
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
2010
Anti-CD40 agonist antibodies: Preclinical and clinical experience
2007
Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts
2008
T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus
2001 StandoutNobel